Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: A propensity-adjusted retrospective cohort study

CNS Drugs

Volumn 18, Issue 15, 2004, Pages 1119-1132

  Valuck, Robert J ^a   Libby, Anne M ^b   Sills, Marion R ^c,d   Giese, Alexis A ^b   Allen, Richard R ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Children's Hospital Colorado   (United States)

^d CHILDREN S HOSPITAL   (United States)

^e Peak Statistical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; DATA BASE; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GEOGRAPHIC DISTRIBUTION; HAZARD ASSESSMENT; HEALTH INSURANCE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANAGED CARE; MEDICAID; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE; SUICIDAL BEHAVIOR; SUICIDE; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; CHILD; COHORT STUDIES; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MANAGED CARE PROGRAMS; MEDICAID; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SUICIDE, ATTEMPTED; UNITED STATES;

EID: 10844242073     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418150-00006     Document Type: Article

References (64)

1. Mitka M. FDA alert on antidepressants for youth. JAMA 2003; 290 (19): 2534
2. Abbott A. British panel bans use of antidepressant to treat children. Nature 2003; 423: 792
3. Food and Drug Administration. FDA public health advisory: suicidality in children and adolescents being treated with antidepressant medications [online]. 2004 Oct 15. Available from URL: http://www.fda.gov/cder/drug/antidepressants/ SS-RIPHA200410.htm [Accessed 2004 Oct 29]
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003; 289 (23): 3095-105
5. Birmaher B, Ryan ND, Williamson D, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35 (11): 1427-39
6. Birmaher B, Arbelaez C, Brent D. Course and outcome of child and adolescent major depressive disorder. Child Adolesc Psychiatr Clin N Am 2002; 11 (3): 619-37
7. Voelker R. Researchers probe depression in children. JAMA 2003; 289 (23): 3078-9
8. Weissman M, Wolk S, Wickramaratne P, et al. Children with prepubertal-onset major depressive disorder and anxiety grown up. Arch Gen Psychiatry. 1999; 56: 794-801
9. Weissman M, Wolk S, Goldstein R, et al. Depressed adolescents grown up. JAMA 1999; 281: 1707-13
10. Berndt E, Koran L, Finkelstein S, et al. Lost human capital from early-onset chronic depression. Am J Psychiatry 2000; 157: 940-7
11. Birmaher B, Brent DA, Benson RS. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 1998; 37(10): 63S-83S
12. Emslie G, Rush A, Weinberg W, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031-7
13. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized clinical Trials. JAMA 2003; 290 (8): 1033-93
14. Emslie G, Heiligenstein J, Wagner K, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205-15
15. Keller M, Ryan N, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762-72
16. Varley C. Psychopharmocological treatment of major depressive disorder in children and adolescents. JAMA 2003; 290 (8): 1091-3
17. Brent D, Birmaher B. British warning on SSRIs questioned. J Am Acad Child Adolesc Psychiatry 2004; 43 (4): 379-80
18. Hazell P, O'Connell D, Heathcote D, et al. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995; 310: 897-901
19. Shireman T, Olson BM, Dewan NA. Patterns of antidepressant use among children and adolescents. Psychiatr Serv (Chic) 2002; 53 (11): 1444-50
20. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51 Suppl.: 60-9
21. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Value Health 1999; 2 (4): 269-80
22. Hoagwood K, Burns BJ, Kiser L, et al. Evidence-based practice in child and adolescent mental health services. Psychiatr Serv (Chic) 2001; 52 (9): 1179-89
23. New Freedom Commission on Mental Health. Achieving the promise: transforming mental health care in America. Final report. Rockville, MD: DHHS; 2003. Pub. No. SMA-03-3832
24. Horesh N, Orbach I, Gothelf D, et al. Comparison of the suicidal behavior of adolescent inpatients with borderline personality disorder and major depression. J Nerv Ment Dis 2003; 191 (9): 582-8
25. Zametkin AJ, Atler MR, Yemeni T. Suicide in teenagers: assessment, management, and prevention. JAMA 2001; 286 (24): 3120-5
26. Keith CR. Adolescent suicide. JAMA 2001; 286 (24): 3126-7
27. Anderson R. Deaths: leading causes for 2000. National Vital Statistics Report. 2002; 50: 1-85
28. Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 2003; 326: 1-5
29. Olfson M, Shaffer D, Marcus SC, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978-82
30. Jick H, Kaye J, Jick S. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292 (3): 338-43
31. Russell M, Taylor D, Cummins G, et al. Use of managed care claims data in the risk assessment of venous thromboembolism in outpatients. Am J Manag Care 2002; 8 (1 Suppl.): S3-9
32. Valuck R. Treatment of depression with citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine in managed care. Part 1: drug selection, dosing, and utilization. Drug Benefit Trends 2002; 14 (7): 23-30
33. Valuck R. Treatment of depression with citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine in managed care. Part 2: patient comorbidities and coprescribed therapies. Drug Benefit Trends 2002; 14 (8): 33-40
34. World Health Organization. ICD-9: international statistical classification of diseases and relation health problems. 9th rev. Geneva: World Health Organization, 1978
35. World Health Organization. ICD-10: international statistical classification of diseases and relation health problems. 10th rev. Geneva: World Health Organization, 1994
36. O'Carroll PW, Potter LB. Suicide contagion and the reporting of suicide: recommendations from a national workshop. Morb Mortal Wkly Rep 1994; 43 (RR-6): 9-18
37. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association, 1994
38. Martin A, Van Hoof T, Stubbe D, et al. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatric Services 2003; 54(1): 72-7
39. Malone D, Billups S, Valuck R, et al. Development of a chronic disease indicator score using a Veterans Affairs Medical Center medication database. J Clin Epidemiol 1999; 52: 551-7
40. Valuck R, Williams S, MacArthur M, et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 2003; 25: 2936-57
41. Rey M, Schulz P, Costa C, et al. Guidelines for the dosage of neuroleptics: I. Chloropromazine equivalents of orally administered neuroleptics. Int Clin Psychiatry 1989; 4: 95-104
42. Rijcken C, Monster T, Brouwers J, et al. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacology 2003; 23 (6): 657-9
43. Foley K. The treatment of cancer pain. N Engl J Med 1985; 313 (2): 84-95
44. Asburn M, Lipman A. Management of pain in the cancer patient. Anesth Analg 1994; 79 (3): 612-4
45. Steiner J, Prochazka A. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105-16
46. Current Procedural Terminology. 4th ed. Chicago (IL): American Medical Association, 2000
47. Wang J, Donnan P. Propensity score methods in drug safety studies: practice, strengths, and limitations. Pharmacoepidemiol Drug Saf 2001; 10: 341-4
48. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-202
49. Crown W, Treglia M, Meneades L, et al. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health 2001; 4 (4): 295-307
50. SAS Language [computer program]. Version 8.1. Cary (NC): SAS Institute, 2000
51. Wong I, Besag F, Santosh P, et al. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004; 27 (13): 991-1000
52. Cook TD, Campbell DT. Quasi-experimentation: design and analysis issues for field settings. Chicago (IL): Rand McNally, 1979
53. Vorstman J, Lahuis B, Buitelaar JK. SSRIs associated with behavioral activation and suicidal ideation. J Am Acad Child Adolesc Psychiatry 2001; 40 (12): 1364-5
54. American Psychiatric Association, et al. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157 (4): 1-45
55. Goldstein B, Goodnick P. Selective serotonin reuptake inhibitors in the treatment of affective disorders: III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998; 12 Suppl. B: S57A
56. Aguglia E, Casacchia M, Cassano G, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8 (3): 197-202
57. Montgomery SA, Huusom AK. Escitalopram is at least as effective as venlafaxine XR in the treatment of depression and is better tolerated [poster]. 15th Congress of the European College of Neuropsychopharmacology; 2002 Oct 5-9; Barcelona
58. Bielski R, Ventura D, Chang C. A double-blind comparison of escitalopram with venlafaxine XR in the treatment of major depressive disorder [poster]. 16th Congress of the European College of Neuropsychopharmacology; 2003 Sep 20-24; Prague
59. Valuck R. Selective serotonin reuptake inhibitors: a class review. Pharmacy and Therapeutics. 2004; 29 (4): 234-43
60. Schlesselman J. Sample size requirements in cohort and case-control studies of disease. Am J Epidemiol 1974; 99: 381-4.
61. Spettell C, Wall T, Allison J, et al. Identifying physician-recognized depression from administrative data: consequences for quality measurement. Health Serv Res 2003; 38 (4): 1081-102
62. Rost K, Smith R, Matthews D, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994; 3 (4): 333-7
63. Hirschfeld R, Keller M, Panico S, et al. The National Depressive and Manie-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277 (4): 333-40
64. Lemelin J, Hotz S, Swensen R, et al. Depression in primary care: why do we miss the diagnosis? Can Fam Physician 1994; 40: 104-8